- Home
- TARS vs BRVE Comparison
TARS vs BRVE Comparison
Compare TARS & BRVE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
Current Price
$71.93
N/A
Current Price
$28.79
Company Overview
Basic Information| Metric | TARS | BRVE |
|---|---|---|
| Founded | 2016 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7B | 2.2B |
| IPO Year | 2020 | 2026 |
Fundamental Metrics
Financial Performance| Metric | TARS | BRVE |
|---|---|---|
| Price | $71.93 | $28.79 |
| Analyst Decision | Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $89.00 | N/A |
| AVG Volume (30 Days) | ★ 668.4K | 376.9K |
| Earning Date | 05-06-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 48.21 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $451,360,000.00 | N/A |
| Revenue This Year | $56.43 | N/A |
| Revenue Next Year | $30.19 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 146.71 | N/A |
| 52 Week Low | $48.20 | $24.61 |
| 52 Week High | $85.25 | $32.00 |
Technical Indicators
Market Signals| Indicator | TARS | BRVE |
|---|---|---|
| Relative Strength Index (RSI) | 67.86 | 39.31 |
| Support Level | $60.95 | $24.61 |
| Resistance Level | $74.39 | $30.12 |
| Average True Range (ATR) | 3.06 | 2.29 |
| MACD | 0.54 | 0.05 |
| Stochastic Oscillator | 95.61 | 49.80 |
Price Performance
Historical Comparison TARS
BRVE
About TARS Tarsus Pharmaceuticals Inc.
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis. TP-04 for the potential treatment of ocular rosacea and TP-05 for potential Lyme disease prophylaxis and community malaria reduction.